Ovarian cancer remains one of the most lethal gynecological malignancies in the world. The five-year survival rate for advanced-stage disease sits at around 30 percent, largely because most cases are diagnosed late and because resistance to standard chemotherapy is common and difficult to overcome.
Behind every drug candidate tested against ovarian cancer, there is a cell line. These in vitro models are the first stop in the drug discovery pipeline, the systems in which researchers identify targets, test compounds, study resistance mechanisms, and decide what to take forward into animal studies and eventually clinical trials.
This guide covers the most widely used ovarian cancer cell lines, what each one models, and how researchers choose the right tool for their specific research question.
Why Ovarian Cancer Cell Lines Are So Important
Ovarian cancer is not a single disease. It is a collection of biologically distinct subtypes with different origins, genetic profiles, clinical behaviors, and responses to treatment. High-grade serous ovarian carcinoma (HGSOC) accounts for around 70 percent of ovarian cancer deaths and is characterized by TP53 mutations and widespread chromosomal instability. Clear cell carcinoma, endometrioid carcinoma, and mucinous carcinoma each represent distinct subtypes with different molecular drivers and drug sensitivities.
This diversity means that no single cell line can serve as a universal model for ovarian cancer research. Researchers need a panel of well-characterized lines that together represent the spectrum of disease biology. Understanding what each line models, and where its limitations lie, is essential for designing experiments that produce meaningful and translatable results.
Key Ovarian Cancer Cell Lines Researchers Use
SKOV3
SKOV3 is one of the most widely used ovarian cancer cell lines in the world. It was derived from the ascites fluid of a patient with ovarian adenocarcinoma and has been in use since the 1970s. SKOV3 cells are frequently used in studies of tumor invasion, metastasis, and drug resistance.
One important characteristic of SKOV3 is that it lacks functional p53, which is relevant given that TP53 mutation is the defining feature of high-grade serous ovarian carcinoma. SKOV3 cells are also known to overexpress HER2, making them a useful model for studying HER2-targeted therapies in an ovarian context.
SKOV3 is highly tumorigenic in mouse xenograft models when injected intraperitoneally or subcutaneously, which makes it a common choice for in vivo experiments evaluating drug efficacy. However, researchers should be aware that extended passaging of SKOV3 can lead to phenotypic divergence between strains, even when STR profiling confirms genetic identity. A 2025 study published in Disease Models and Mechanisms documented this divergence specifically in SKOV3, highlighting the importance of using low-passage stocks and performing regular quality checks.
A2780
A2780 is among the most extensively characterized ovarian cancer cell lines available. It was established from an untreated patient with ovarian carcinoma and is highly sensitive to both cisplatin and paclitaxel, the two backbone drugs of standard ovarian cancer chemotherapy. This sensitivity makes A2780 a valuable baseline model for platinum and taxane research.
What makes A2780 particularly powerful as a research tool is the family of isogenic resistant variants that have been developed from it. A2780CisR is resistant to cisplatin, A2780ADR is resistant to adriamycin (doxorubicin), and A2780PTX variants represent stepwise taxane resistance. These paired sensitive and resistant lines allow researchers to directly compare the molecular changes that accompany treatment resistance, identifying potential targets for overcoming it.
A2780 also carries wild-type TP53, which distinguishes it from HGSOC biology but makes it useful for studying how p53 status influences drug response and resistance mechanisms.
OVCAR3
OVCAR3 was established from a patient with progressive ovarian adenocarcinoma who had been treated with multiple chemotherapy regimens. It is one of the most clinically relevant models for high-grade serous ovarian carcinoma, the subtype responsible for the majority of ovarian cancer deaths.
OVCAR3 cells carry mutant TP53, which aligns with the biology of HGSOC. A 2025 study published in Oncoscience used DNA sequencing and cell death analysis to validate OVCAR3 as a reliable model for HGSOC, confirming that its genetic profile closely reflects that of clinical HGSOC samples. This validation has reinforced OVCAR3's standing as one of the preferred lines for studying the most lethal ovarian cancer subtype.
OVCAR3 is also a component of the NCI-60 cell line panel, the National Cancer Institute's collection of human cancer cell lines used for large-scale drug screening. This inclusion means that extensive pharmacological data is publicly available for OVCAR3, making it easier for researchers to contextualize their own findings.
CAOV3
CAOV3 is another well-established ovarian adenocarcinoma cell line, derived from the solid tumor of an ovarian cancer patient. It carries mutant TP53 and represents high-grade disease. CAOV3 is frequently used in comparative studies and in panels alongside OVCAR3 and SKOV3 to evaluate drug responses across multiple HGSOC models.
CAOV3 forms tumors when injected intraperitoneally in immunodeficient mice, making it a viable option for in vivo efficacy studies. Its inclusion in several published ovarian cancer cell line panels, including studies by ATCC and independent academic groups, has generated a substantial body of reference data.
ES2
ES2 is a cell line derived from an ovarian clear cell carcinoma, a subtype that is notably resistant to standard platinum-based chemotherapy and has a poorer prognosis than most other ovarian cancer subtypes. ES2 cells are used specifically to model clear cell carcinoma biology and to screen drugs that might be effective against this treatment-refractory subtype.
ES2 is one of the most aggressive ovarian cancer cell lines, with a median survival time of under 30 days in intraperitoneal mouse models. This aggressive growth phenotype, while challenging to work with, makes ES2 useful for rapidly evaluating whether a compound has meaningful anti-tumor activity.
OV90
OV90 was derived from malignant ascites of a patient with stage IIIC papillary serous ovarian carcinoma. This origin, from ascitic fluid rather than solid tumor, makes OV90 a relevant model for studying peritoneal dissemination and the biology of ovarian cancer metastasis in the abdominal cavity.
OV90 carries TP53 mutation and represents a late-stage, aggressive disease phenotype. It is used in studies of invasion, adhesion, and the interaction between tumor cells and the peritoneal microenvironment.
PEO1 and PEO4
The PEO series represents something rare in cancer cell line panels: paired lines derived from the same patient at different points in the disease course. PEO1 was established from a cisplatin-sensitive tumor, and PEO4 was established from the same patient's tumor after it developed platinum resistance following treatment.
PEO1 carries a pathogenic BRCA2 mutation, which makes it sensitive to PARP inhibitors, a class of drugs that exploit defects in homologous recombination DNA repair. PEO4 carries a secondary BRCA2 reversion mutation that restores partial repair function and confers resistance to PARP inhibitors.
This pair is used extensively in BRCA-related research and in studies evaluating the mechanisms of PARP inhibitor resistance, which has become a central challenge in ovarian cancer clinical management.
IGROV1
IGROV1 is an ovarian carcinoma cell line frequently used in studies of invasion, peritoneal metastasis, and drug resistance. It is one of the lines in the NCI-60 panel and has been used in numerous studies evaluating cytotoxic agents and targeted therapies. IGROV1 is known to form spheroids under non-adherent conditions, which is relevant for modeling the ascitic growth pattern characteristic of advanced ovarian cancer.
How Researchers Choose the Right Cell Line
With so many ovarian cancer cell lines available, selecting the right model depends on the specific research question being asked.
Histological Subtype
If the goal is to model high-grade serous ovarian carcinoma, the most clinically relevant subtype, lines such as OVCAR3, CAOV3, OV90, and PEO1 are appropriate choices. For clear cell carcinoma, ES2 is one of the few lines that authentically represents this subtype. Mucinous and endometrioid subtypes have even fewer well-validated cell line models, which is an acknowledged gap in the field.
Drug Sensitivity or Resistance
For drug discovery and screening applications, the choice between sensitive and resistant lines is critical. If the goal is to identify compounds that overcome platinum resistance, working with A2780CisR or the PEO1/PEO4 pair alongside their sensitive counterparts provides the most informative experimental design.
BRCA Status
For research into PARP inhibitors or homologous recombination repair, cell lines with known BRCA1 or BRCA2 mutation status are essential. PEO1 and UWB1.289 are among the best-characterized BRCA-mutant ovarian cancer lines available.
In Vivo Compatibility
Not all ovarian cancer cell lines form tumors reliably in mouse xenograft models. A2780, OVCAR3, SKOV3, and ES2 are among those with established in vivo tumorigenicity when injected intraperitoneally or subcutaneously into immunodeficient mice. Researchers planning to bridge in vitro findings into animal studies should verify tumorigenicity data for their chosen lines before committing to a model.
The Importance of Using Authenticated Cell Lines
All of the considerations above become meaningless if the cell line being used is not what it claims to be. Ovarian cancer cell line misidentification has been documented in the scientific literature, with lines such as SKOV3 and A2780 being among those where contamination or mislabeling has historically occurred.
Authenticated ovarian cancer cell lines with documented STR profiles are the only reliable starting point for research intended for publication. Many journals now require proof of authentication before accepting manuscripts, and funding agencies including the NIH expect authentication to be built into research designs from the outset.
Emerging Models: Beyond Traditional 2D Cell Lines
Traditional two-dimensional cell culture on flat plastic surfaces does not fully capture the biology of solid tumors or the peritoneal metastasis pattern characteristic of ovarian cancer. Several newer model systems are being used alongside conventional cell lines to provide more physiologically relevant data.
Spheroid cultures, where cells grow in three-dimensional aggregates under non-adherent conditions, better mimic the architecture of tumor masses and ascitic cell clusters. Multiple ovarian cancer lines including OVCAR3, IGROV1, and A2780 have been shown to form spheroids, and researchers use these 3D cultures to study drug penetration, tumor hypoxia, and stem-like cell behavior.
Patient-derived organoids, grown directly from tumor biopsies or ascitic fluid, represent the next generation of ovarian cancer models. These systems preserve the genetic and histological heterogeneity of patient tumors more faithfully than established cell lines, making them powerful tools for personalized medicine research and predictive drug screening. They are, however, technically demanding and not yet standardized across labs in the way that established lines are.
For most researchers, established ovarian cancer cell lines remain the practical foundation of drug discovery work, with newer 3D and patient-derived models serving as validation systems for findings generated in conventional cultures.
Frequently Asked Questions
What is the most commonly used ovarian cancer cell line?
SKOV3, A2780, and OVCAR3 are among the most widely used. Each has different characteristics: SKOV3 for invasion and metastasis studies, A2780 for chemosensitivity and resistance research, and OVCAR3 for modeling high-grade serous ovarian carcinoma.
Which ovarian cancer cell lines carry BRCA mutations?
PEO1 carries a pathogenic BRCA2 mutation and is sensitive to PARP inhibitors. UWB1.289 carries a BRCA1 mutation and is another commonly used BRCA-deficient line for studying homologous recombination repair deficiency.
What is the difference between A2780 and A2780CisR?
A2780 is the parental, cisplatin-sensitive line. A2780CisR is a derivative developed through stepwise exposure to cisplatin and displays acquired resistance to platinum compounds. Together they are used to study resistance mechanisms and identify strategies to overcome them.
Is OVCAR3 a good model for high-grade serous ovarian carcinoma?
Yes. OVCAR3 carries mutant TP53, which is the hallmark of HGSOC. A 2025 study validated OVCAR3 as a reliable HGSOC model by confirming its genetic profile against clinical samples. It is included in the NCI-60 panel and has extensive published pharmacological data.
Which ovarian cancer cell line is best for peritoneal metastasis studies?
OV90, derived from ascitic fluid, and IGROV1 are commonly used for peritoneal dissemination studies. SKOV3 and A2780 are also tumorigenic after intraperitoneal injection in mouse models and are used for in vivo peritoneal metastasis experiments.
Do ovarian cancer cell lines require authentication?
Yes. All cell lines used in research intended for publication or regulatory submission should be authenticated using STR profiling. Lines like SKOV3 and A2780 have documented histories of contamination issues, making authentication particularly important when working with these models.
Are organoids replacing traditional ovarian cancer cell lines?
Not yet. Patient-derived organoids offer better biological fidelity but are technically demanding and not yet standardized. Established cell lines remain the practical foundation of most drug discovery workflows, with organoids increasingly used as validation tools for key findings.